Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cellectis ADR representing Ord Shs CLLS

Healthcare Biotechnology
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CLLS)

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

GlobeNewswire November 5, 2024

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

GlobeNewswire November 4, 2024

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

GlobeNewswire October 30, 2024

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

GlobeNewswire October 22, 2024

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

GlobeNewswire September 3, 2024

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

GlobeNewswire August 26, 2024

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

GlobeNewswire August 7, 2024

Cellectis Provides Financial Results for the Second Quarter 2024

GlobeNewswire August 6, 2024

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

GlobeNewswire August 1, 2024
View More News ››

Opinion & Analysis (NDAQ:CLLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CLLS)

Cellectis Appoints Arthur Stril as Interim Chief Financial O

Breaking News: $CLLS Cellectis Appoints Arthur Stril as Interim Chief Financial Officer | BenzingaNEW YORK, May 02, 2024 (GLOBE NEWSWIRE...
whytestocks - May 2, 2024

Cellectis Reports Financial Results for the Fourth Quarter a

JUST IN: $CLLS Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023@ Preliminary results of NATHALI-01 and...
whytestocks - April 29, 2024
View more Bullboard ››

AKITA Drilling Ltd

AKITA Drilling Ltd

AKITA Drilling Ltd. provides contract drilling services, primarily to the oil and gas industry, in Canada and the United ...
View More »